Karyopharm Q2 Revenue Falls, Cash Runs Out in September
KPTI is trading near its 52-week low of $1.8 (14% above the low).
Summary
Karyopharm's Q2 revenue declined year-over-year as license revenue dropped, while U.S. XPOVIO net product revenue held steady at $30.8M. The company reaffirmed 2026 total revenue guidance of $130M-$150M but confirmed existing liquidity only funds operations into September 2026. This follows the Phase 3 endometrial cancer trial failure in July and the 8-K filed today showing a widening loss. The cash runway is now critically short, forcing the company to seek financing imminently. Watch for any financing announcement or strategic update before the September cash cliff.
At the time of this announcement, KPTI was trading at $2.06 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $46M. The 52-week trading range was $1.80 to $10.99. This news item was assessed with negative market sentiment and an importance score of 7 out of 10. Source: Reuters.